Long-Term Performance of the COMBO Dual-Therapy Stent: Results from the REMEDEE Registry
Highlights
- • The COMBO stent combines sirolimus with an anti-CD34+ antibody coating designed to promote rapid vascular healing.
- • The REMEDEE Registry evaluates clinical outcomes of 1000 patients treated with COMBO stent.
- • Beyond 2 years, only 1.5% of patients underwent TLR, resulting in 11.9% at 4-year follow-up.
- • Definite stent thrombosis was 0.7% with no ST between 3 and 4 years follow-up.
Abstract
Background
Data of long-term safety and efficacy of the COMBO dual-therapy stent is lacking. REMEDEE Registry evaluated the COMBO stent and showed low clinical event rates up to 3 year. We report the clinical outcomes at 4-year follow-up of this registry.